CMS tells Inside Health Policy that insurers are not required to cover the long-acting, injectable form of pre-exposure prophylaxis (PrEP) until the plan year in effect 12 months after the federal preventive services panel gave the drug an “A” recommendation, but a key patient advocate intends to keep lobbying the agency to more quickly implement the coverage mandate. Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, says the administration has made it clear it is committed to fighting...